Literature DB >> 18245010

Application of PET/CT in the development of novel anticancer drugs.

David S Boss1, Renato Valdes Olmos, Michiel Sinaasappel, Jos H Beijnen, Jan H M Schellens.   

Abstract

Combined positron emission tomography/computed tomography (PET/CT) is a relatively new imaging modality, combining the functional images of PET with the anatomical information of CT. Since its commercial introduction about 5 years ago, PET/CT has become an important tool in oncology. Currently, the technique is used for primary staging and restaging of cancer patients, as well as for surgery and radiation therapy planning. The abilities of PET/CT to measure early treatment response as well as drug distribution within the body make this technique very useful in the development of novel anticancer drugs. In this paper, the recent literature on the current role of PET/CT in drug development is reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245010     DOI: 10.1634/theoncologist.2007-0097

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  14 in total

1.  What oncologists need and require from nuclear medicine.

Authors:  M A Pantaleo; S Fanti; M Nannini; S Boschi; C Nanni; A Maleddu; D Rubello; G Biasco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

2.  Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor.

Authors:  Hagit Dafni; Peder E Z Larson; Simon Hu; Hikari A I Yoshihara; Christopher S Ward; Humsa S Venkatesh; Chunsheng Wang; Xiaoliang Zhang; Daniel B Vigneron; Sabrina M Ronen
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

3.  The current role of PET-CT in the characterization of hepatobiliary malignancies.

Authors:  Ginseppe Garcea; Seok Ling Ong; Guy J Maddern
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

4.  Design and optimization of coin-shaped microreactor chips for PET radiopharmaceutical synthesis.

Authors:  Arkadij M Elizarov; R Michael van Dam; Young Shik Shin; Hartmuth C Kolb; Henry C Padgett; David Stout; Jenny Shu; Jiang Huang; Antoine Daridon; James R Heath
Journal:  J Nucl Med       Date:  2010-02       Impact factor: 10.057

Review 5.  Circulating tumor cell isolation, culture, and downstream molecular analysis.

Authors:  Sandhya Sharma; Rachel Zhuang; Marisa Long; Mirjana Pavlovic; Yunqing Kang; Azhar Ilyas; Waseem Asghar
Journal:  Biotechnol Adv       Date:  2018-03-17       Impact factor: 14.227

Review 6.  Boron chemicals in diagnosis and therapeutics.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Caroline Schinke; Sasmita Das; Suman Kambhampati; Sushanta K Banerjee; Peter Van Veldhuizen; Amit Verma; Louis M Weiss; Todd Evans
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

7.  Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.

Authors:  Jing Li; Seongho Kim; Anthony F Shields; Kirk A Douglas; Christopher I McHugh; Jawana M Lawhorn-Crews; Jianmei Wu; Thomas J Mangner; Patricia M LoRusso
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

8.  Objective assessment of tumour response to therapy based on tumour growth kinetics.

Authors:  E Mehrara; E Forssell-Aronsson; P Bernhardt
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

9.  Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model.

Authors:  M A Pantaleo; L Landuzzi; G Nicoletti; C Nanni; S Boschi; G Piazzi; D Santini; M Di Battista; P Castellucci; F Lodi; S Fanti; P-L Lollini; G Biasco
Journal:  Clin Exp Med       Date:  2009-02-19       Impact factor: 3.984

Review 10.  Detecting circulating tumor cells: current challenges and new trends.

Authors:  Bin Hong; Youli Zu
Journal:  Theranostics       Date:  2013-04-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.